Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference
12 Junho 2023 - 9:00AM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology, today announced that Michael Feldschuh, CEO
and President has been invited to present at the Healthcare Virtual
Conference Part II, presented by Maxim Group LLC and hosted by
M-Vest. The conference is being held virtually on June 20 - 22,
2023.
Mr. Feldschuh will participate in a fireside
chat with Anthony Vendetti, Director of Healthcare and Senior
Analyst at Maxim Group on June 21 at 3:30pm ET.
Investors can register and watch live on M-Vest.
To attend, just sign up to become an M-Vest member.
Click Here to Reserve your seat.
About Daxor:
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the
BVA-100® (Blood Volume Analyzer), the first diagnostic blood
test cleared by the FDA to provide safe, accurate, objective
quantification of blood volume status and composition compared to
patient-specific norms. Over 65,000+ tests have been performed at
leading hospital centers across the U.S., enhancing hospital
performance metrics in a broad range of surgical and medical
conditions, including significantly reducing mortality and
readmissions in heart failure and critical care. Daxor has several
ongoing multicenter trials in the areas of COVID-19 and heart
failure treatment with support from the NIH and is under contract
developing analyzers to improve combat casualty care with the U.S.
Department of Defense. Daxor’s mission is to advance healthcare by
enabling optimal fluid management with blood volume analysis.
Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign
up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements:
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024